The Inaccuracy of Patient Recall for COPD Exacerbation Rate Estimation and Its Implications Results from Central Adjudication

被引:27
作者
Frei, Anja [1 ]
Siebeling, Lara [3 ]
Wolters, Callista [1 ]
Held, Leonhard [1 ]
Muggensturm, Patrick [1 ,2 ]
Strassmann, Alexandra [1 ]
Zoller, Marco [4 ]
ter Riet, Gerben [3 ]
Puhan, Milo A. [1 ]
机构
[1] Univ Zurich, Epidemiol Biostat & Prevent Inst, Hirschengraben 84, CH-8001 Zurich, Switzerland
[2] Zollikerberg Hosp, Dept Internal Med, Zollikon, Switzerland
[3] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, NL-1012 WX Amsterdam, Netherlands
[4] Univ Zurich, Inst Gen Practice & Hlth Serv Res, Zurich, Switzerland
基金
瑞士国家科学基金会;
关键词
adjudication committee; COPD; end point; exacerbation; outcome measurement error; sample size; QUALITY-OF-LIFE; OBSTRUCTIVE PULMONARY-DISEASE; CAUSE-SPECIFIC MORTALITY; LUNG-FUNCTION; TRIAL; MISCLASSIFICATION; OUTCOMES; EVENTS;
D O I
10.1016/j.chest.2016.06.031
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
BACKGROUND: COPD exacerbation incidence rates are often ascertained retrospectively through patient recall and self-reports. We compared exacerbation ascertainment through patient self-reports and single-physician chart review to central adjudication by a committee and explored determinants and consequences of misclassification. METHODS: Self-reported exacerbations (event-based definition) in 409 primary care patients with COPD participating in the International Collaborative Effort on Chronic Obstructive Lung Disease: Exacerbation Risk Index Cohorts (ICE COLD ERIC) cohort were ascertained every 6 months over 3 years. Exacerbations were adjudicated by single experienced physicians and an adjudication committee who had information from patient charts. We assessed the accuracy (sensitivities and specificities) of self-reports and single-physician chart review against a central adjudication committee (AC) (reference standard). We used multinomial logistic regression and bootstrap stability analyses to explore determinants of misclassifications. RESULTS: The AC identified 648 exacerbations, corresponding to an incidence rate of 0.60 +/- 0.83 exacerbations/patient-year and a cumulative incidence proportion of 58.9%. Patients self-reported 841 exacerbations (incidence rate, 0.75 +/- 1.01; incidence proportion, 59.7%). The sensitivity and specificity of self-reports were 84% and 76%, respectively, those of single-physician chart review were between 89% and 96% and 87% and 99%, respectively. The multinomial regression model and bootstrap selection showed that having experienced more exacerbations was the only factor consistently associated with underreporting and overreporting of exacerbations (underreporters: relative risk ratio [RRR], 2.16; 95% CI, 1.76-2.65 and overreporters: RRR, 1.67; 95% CI, 1.39-2.00). CONCLUSIONS: Patient 6-month recall of exacerbation events are inaccurate. This may lead to inaccurate estimates of incidence measures and underestimation of treatment effects. The use of multiple data sources combined with event adjudication could substantially reduce sample size requirements and possibly cost of studies.
引用
收藏
页码:860 / 868
页数:9
相关论文
共 32 条
[1]   Counting, analysing and reporting exacerbations of COPD in randomised controlled trials [J].
Aaron, S. D. ;
Fergusson, D. ;
Marks, G. B. ;
Suissa, S. ;
Vandemheen, K. L. ;
Doucette, S. ;
Maltais, F. ;
Bourbeau, J. F. ;
Goldstein, R. S. ;
Balter, M. ;
O'Donnell, D. ;
FitzGerald, M. .
THORAX, 2008, 63 (02) :122-128
[2]   Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease [J].
Calverley, Peter M. A. ;
Anderson, Julie A. ;
Celli, Bartolome ;
Ferguson, Gary T. ;
Jenkins, Christine ;
Jones, Paul W. ;
Yates, Julie C. ;
Vestbo, Jorgen ;
Calverley, P. M. A. ;
Anderson, J. A. ;
Celli, B. ;
Ferguson, G. T. ;
Jenkins, C. ;
Jones, P. W. ;
Knobil, K. ;
Yates, J. C. ;
Vestbo, J. ;
Cherniack, R. ;
Similowski, T. ;
Cleland, J. ;
Whitehead, A. ;
Wise, R. ;
McGarvey, L. ;
John, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (08) :775-789
[3]   Outcomes for COPD pharmacological trials:: from lung function to biomarkers [J].
Cazzola, M. ;
MacNee, W. ;
Martinez, F. J. ;
Rabe, K. F. ;
Franciosi, L. G. ;
Barnes, P. J. ;
Brusasco, V. ;
Burge, P. S. ;
Calverley, P. M. A. ;
Celli, B. R. ;
Jones, P. W. ;
Mahler, D. A. ;
Make, B. ;
Miravitlles, M. ;
Page, C. P. ;
Palange, P. ;
Parr, D. ;
Pistolesi, M. ;
Rennard, S. I. ;
Moelken, M. P. Rutten-Van ;
Stockley, R. ;
Sullivan, S. D. ;
Wedzicha, J. A. ;
Wouters, E. F. .
EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (02) :416-468
[4]   Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial [J].
Connolly, S. ;
Pogue, J. ;
Hart, R. ;
Pfeffer, M. ;
Hohnloser, S. ;
Chrolavicius, S. ;
Yusuf, S. .
LANCET, 2006, 367 (9526) :1903-1912
[5]   Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease [J].
Donaldson, GC ;
Seemungal, TAR ;
Bhowmik, A ;
Wedzicha, JA .
THORAX, 2002, 57 (10) :847-852
[6]   Definitions of Exacerbations Does It Really Matter in Clinical Trials on COPD? [J].
Effing, Tanja W. ;
Kerstjens, Huib A. M. ;
Monninkhof, Evelyn M. ;
van der Valk, Paul D. L. P. M. ;
Wouters, Emiel F. M. ;
Postma, Dirkje S. ;
Zielhuis, Gerhard A. ;
van der Palen, Job .
CHEST, 2009, 136 (03) :918-923
[7]   THE EFFECTS OF EXPOSURE MISCLASSIFICATION ON ESTIMATES OF RELATIVE RISK [J].
FLEGAL, KM ;
BROWNIE, C ;
HAAS, JD .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1986, 123 (04) :736-751
[8]   Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index [J].
Frei, Anja ;
Muggensturm, Patrick ;
Putcha, Nirupama ;
Siebeling, Lara ;
Zoller, Marco ;
Boyd, Cynthia M. ;
ter Riet, Gerben ;
Puhan, Milo A. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2014, 67 (08) :904-911
[9]   A MEASURE OF QUALITY-OF-LIFE FOR CLINICAL-TRIALS IN CHRONIC LUNG-DISEASE [J].
GUYATT, GH ;
BERMAN, LB ;
TOWNSEND, M ;
PUGSLEY, SO ;
CHAMBERS, LW .
THORAX, 1987, 42 (10) :773-778
[10]   Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial [J].
Hata, Jun ;
Arima, Hisatomi ;
Zoungas, Sophia ;
Fulcher, Greg ;
Pollock, Carol ;
Adams, Mark ;
Watson, John ;
Joshi, Rohina ;
Kengne, Andre Pascal ;
Ninomiya, Toshiharu ;
Anderson, Craig ;
Woodward, Mark ;
Patel, Anushka ;
Mancia, Giuseppe ;
Poulter, Neil ;
MacMahon, Stephen ;
Chalmers, John ;
Neal, Bruce .
PLOS ONE, 2013, 8 (02)